SANA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Dec 2023 @ 16:00):
Our systems believe the stock currently is undervalued by 0.23% compare to its pairs and should correct upwards.

Stats
Today's Volume	1.52M
Average Volume	1.34M
Market Cap	806.27M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.86
ATR14	$0.580 (14.25%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-02	Williams Douglas E	Buy	10 000	Restricted Stock Units
2023-11-02	Hordo Christian	Buy	10 000	Restricted Stock Units
2023-11-02	Hardy Nathan	Buy	10 000	Restricted Stock Units
2023-10-05	Wilderotter Mary Agnes	Buy	2 077	Common Stock
2023-10-05	Bishop Hans Edgar	Buy	6 925	Common Stock

INSIDER POWER
-65.63
Last 99 transactions
Buy: 5 204 220 \| Sell: 12 096 393

Correlation (AI algo v.1.1b): Undervalued: 0.23% $4.08 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.68 (moderate)

Short: 0.77 (moderate)

Signal:(67) Neutral

Sana Biotechnology, Inc. Correlation

10 Most Positive Correlations
ALVR	0.839
MDVL	0.839
TCRT	0.836
USEG	0.834
HOOK	0.832
TLSA	0.832
GRAY	0.828
INFI	0.824
OPK	0.815
RUBY	0.815

10 Most Negative Correlations
BNIXU	-0.875
MICT	-0.812

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sana Biotechnology, Inc. Correlation - Currency/Commodity

-0.04
( neutral )

0.18
( neutral )

0.00
( neutral )

-0.05
( neutral )

Sana Biotechnology, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.410

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.0050

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.590

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.420

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.